Skip to main content

Orchard Therapeutics, a global gene therapy leader, and Pharming Group, a global, commercial stage biopharmaceutical company, today announced a strategic collaboration to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.

This a significant first step in developing a potentially transformative one-time treatment for HAE

- Sijmen de Vries - CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline